title: Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.
abstract: A phase I trial was performed to assess the immunomodulatory activities, maximum tolerated doses, and the toxicity of recombinant interleukin-2 (rIL-2) administered in combination with doxorubicin to patients with refractory malignancies. Therapy was administered to successive cohorts of four to six patients who were treated at three different dose levels (1A, 1B, 2A). Levels 1-2 refer to doxorubicin (40 or 60 mg/m2) given as an intravenous (i.v.) bolus on day 1, and levels A-B refer to rIL-2 (1.0 or 3.0 x 10(6) U/m2) given as a continuous i.v. infusion on days 2-5, 9-12, and 16-19. Cycles were repeated every 28 days. Seventeen patients were entered in the trial. Dose limiting toxicity consisted of neutropenia, and the maximum tolerated dose (MTD) of the combination was doxorubicin 40 mg/m2 and rIL-2 3.0 x 10(6) U/m2. No objective responses were observed. Lymphocytosis related to rIL-2 occurred and flow cytometry demonstrated significant increases in the following subsets: CD3+CD25+HLADr+ and CD11b-CD16c+CD8-. Natural killer cell activity and lymphokine-activated killer (LAK) cell precursors were increased in patients treated at dose levels 1A and 1B (40 mg/m2 doxorubicin), but no consistent changes in LAK activity were noted. No clinical responses were seen and the overall toxicity of this combination was moderate to severe. Administration of doxorubicin prior to rIL-2 does not enhance the immunologic effects of rIL-2.
authors.affiliation: Department of Experimental Therapeutics, Cleveland Clinic Cancer Center, Ohio 44195-5236.
authors.forename: R M
authors.initials: RM
authors.lastname: Bukowski
authors.forename: J S
authors.initials: JS
authors.lastname: Sergi
authors.forename: G T
authors.initials: GT
authors.lastname: Budd
authors.forename: S
authors.initials: S
authors.lastname: Murthy
authors.forename: R
authors.initials: R
authors.lastname: Tubbs
authors.forename: V
authors.initials: V
authors.lastname: Gibson
authors.forename: L
authors.initials: L
authors.lastname: Bauer
authors.forename: J
authors.initials: J
authors.lastname: Stanley
authors.forename: S
authors.initials: S
authors.lastname: Gautam
authors.forename: J
authors.initials: J
authors.lastname: Finke
mesh_terms: D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
chemical_list: D007376:Interleukin-2; D004317:Doxorubicin